Innate Pharma S.A.
IPHA
$1.93
-$0.04-2.03%
NASDAQ
| 06/30/2024 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -0.85% | -49.49% | |||
| Total Other Revenue | -0.85% | -16.38% | |||
| Total Revenue | -0.85% | -41.95% | |||
| Cost of Revenue | -0.85% | 19.33% | |||
| Gross Profit | 0.85% | -439.70% | |||
| SG&A Expenses | -0.85% | 5.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.85% | 15.63% | |||
| Operating Income | 0.85% | -116.24% | |||
| Income Before Tax | 0.85% | -168.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.85% | -168.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.85% | -168.86% | |||
| EBIT | 0.85% | -116.24% | |||
| EBITDA | 0.85% | -147.95% | |||
| EPS Basic | 0.84% | -168.06% | |||
| Normalized Basic EPS | 0.87% | -167.78% | |||
| EPS Diluted | 0.89% | -171.45% | |||
| Normalized Diluted EPS | 0.87% | -167.78% | |||
| Average Basic Shares Outstanding | 0.00% | 0.35% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||